Sol-Gel Technologies: Downgrading To 'Hold' As Success Relies On Upcoming Q4 Catalyst
2026-01-16 15:00:38 ET
The last time I spoke about Sol-Gel Technologies ( SLGL ), it was with respect to a Seeking Alpha article entitled “ Sol-Gel Shines In Treating 2 Skin Disorders, NDAs Expected For Both Indications In 2020 .” With respect to this article, I noted that the company was gearing up to receive FDA approvals for its drugs TWYNEO for acne vulgaris in adults and pediatric patients ages 9 and older and EPSOLAY for the treatment of inflammatory lesions for adults with Rosacea. Both of these drugs are alright but are no longer the key drivers of value for the company that investors should be looking at. A second update is that this company has been hard at work developing its topical hedgehog signaling pathway inhibitor SGT-610 for patients with Gorlin Syndrome....
Read the full article on Seeking Alpha
For further details see:
Sol-Gel Technologies: Downgrading To 'Hold' As Success Relies On Upcoming Q4 Catalyst
NASDAQ: SLGL
SLGL Trading
-4.38% G/L:
$76.50 Last:
36,271 Volume:
$75.445 Open:
